Prostate cancer urine test identifies good prognosis for patients

03 November 2021

A new pilot study published today reveals how urine biomarkers can show the amount of significant cancer in a prostate, highlighting with more certainty which men need treatment.

Researchers at the University of East Anglia and the Earlham Institute (EI) have shown that a prostate cancer urine test can identify men at ‘intermediate risk’ who can safely avoid immediate treatment and benefit from ‘active surveillance’ instead.

Previously, the team’s Prostate Urine Risk (PUR) test could identify men with high and low risk cancers - but can now help men with intermediate-risk disease - for whom treatment options had been less clear.

Prostate cancer is the most common cancer in men in the UK. It usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. 

The most commonly-used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination (DRE), an MRI scan and an invasive biopsy. However, doctors struggle to predict which tumours will progress to a more aggressive form, making it hard to decide on treatment for many men.

Lead researcher Dr Jeremy Clark, from UEA’s Norwich Medical School, said: “While prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from.

“Therefore, there is a desperate need for improvements in diagnosing and predicting outcomes for prostate cancer patients to minimise overdiagnosis and overtreatment while appropriately treating men with aggressive disease, especially if this can be done without taking an invasive biopsy.

“Here at the UEA, we have developed a urine test for prostate cancer called the Prostate Urine Risk Test – or PUR for short.

“The ‘risk’ here refers to the aggressiveness of the cancer and its potential to spread to other organs, which would eventually kill the patient. But prostate cancer is very complex and risk levels vary widely between men. 

“Previously, we have shown that PUR can identify men with high-risk cancer which requires immediate treatment and also low-risk cancer that has a very low rate of progression and does not generally need treatment.

“But there is a third category of men with ‘intermediate-risk’, which falls in between these extremes. Around half of men diagnosed with prostate cancer fall into this group and the treatment pathways for them have been less clear, until now.

“It is known that disease progression in intermediate-risk men is associated with the presence of increasing amounts of Gleason pattern 4 cancer in their prostate. Our study shows that the PUR test can assess the amount of Gleason pattern 4 without the need for a biopsy.

“So, not only can PUR measure the presence of aggressive cancer, but it can also measure increasing amounts of aggressive cancer in the prostate. 

“This means that it can show us which men at intermediate risk may require treatment and which may instead be managed conservatively with surveillance.

“PUR will also be useful for monitoring disease in men that do not currently require treatment, and flag up the emergence and expansion of aggressive disease,” he added.

The results of this pilot study will be further investigated in a much larger cohort of men using samples collected with a prostate screening box which the patients receive by mail, and return samples by post directly for analysis at UEA.


Dan Brewer BigCCancerCharity

Image above: Prof. Daniel Brewer at Norwich Medical School, UEA. Picture credit: Big C Cancer Charity. 

Prof Daniel Brewer, also from UEA’s Norwich Medical School and a visiting worker at the Earlham Institute, said: “Our recently developed urine biomarker test for prostate cancer PUR can distinguish whether men should be placed on active surveillance or have radical treatment.

“In this research, we examine in more detail what biological change PUR is detecting. We found there is strong evidence that the PUR score is identifying the amount of highly differentiated tumour cells there are in the prostate. This is an exciting finding that helps explain why PUR works so well.

“This test is currently being validated in a large multiple site study supported by Prostate Cancer UK and Movember,” he added.

Dr Sarah Hsiao, Director, Biomedical Research and Impact at Movember, said: “This new research from Dr Clark’s team shows that the PUR test can be used to estimate the level of a specific pathological characteristic (Gleason Pattern 4) that is linked to increased risk of disease progression in men with prostate cancer. 

“This is important because, for men whose prostate tumour contains varying levels of Gleason Pattern 4, a prostate biopsy is necessary to determine whether men should receive active treatment or be managed by active surveillance. 

“We look forward to seeing further validation of this research in a larger study cohort. If successful, this non-invasive PUR test may be able to support decision-making process without needing an invasive prostate biopsy that is associated with discomfort and risk of infection.”

This study was led by UEA in collaboration with researchers in the Urology and Cellular Pathology departments at the Norfolk and Norwich University Hospital, Hull University Teaching Hospitals NHS Trust, the Institute of Cancer Research, The Royal Marsden, and the Earlham Institute.

It was funded by Movember, Prostate Cancer UK, the Masonic Charitable Foundation, the Bob Champion Cancer Trust, Big C, the King family, the Andy Ripley Memorial Fund, the Hargrave Foundation, the Provincial Grand Lodge of Norfolk and the Tesco Centenary Grant.

‘The Urine Biomarker PUR-4 is Positively Associated with the Amount of Gleason 4 in Human Prostate Cancers’ is published in the journal Life (MDPI) on November 3, 2021.


Notes to editors.

Notes to editors

1/ For more information or to request an interview, please contact the UEA communications office on +44 (0)1603 593496 or email


2/ The University of East Anglia (UEA) is a UK Top 25 university and is ranked in the top 50 globally for research citations. Known for its world-leading research and good student experience, it was awarded Gold in the Teaching Excellence Framework and is a leading member of Norwich Research Park, one of Europe’s biggest concentrations of researchers in the fields of environment, health and plant science.


About Earlham Institute

The Earlham Institute (EI) is a world-leading research Institute focusing on the development of genomics and computational biology. EI is based within the Norwich Research Park and is one of eight institutes that receive strategic funding from Biotechnology and Biological Science Research Council (BBSRC) - £5.43m in 2017/18 - as well as support from other research funders. EI operates a National Capability to promote the application of genomics and bioinformatics to advance bioscience research and innovation.

EI offers a state of the art DNA sequencing facility, unique by its operation of multiple complementary technologies for data generation. The Institute is a UK hub for innovative bioinformatics through research, analysis and interpretation of multiple, complex data sets. It hosts one of the largest computing hardware facilities dedicated to life science research in Europe. It is also actively involved in developing novel platforms to provide access to computational tools and processing capacity for multiple academic and industrial users and promoting applications of computational Bioscience. Additionally, the Institute offers a training programme through courses and workshops, and an outreach programme targeting key stakeholders, and wider public audiences through dialogue and science communication activities.



Tags: Cancer